Read + Share
Nishio T, Koyama Y, Liu X, Rosenthal SB, et al. Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a
strategy for treatment of cholestatic liver fibrosis. Proc Natl Acad Sci U S A 2021;118.
PMID: 34253615
|
 |
|
Nishio T, Koyama Y, Liu X, Rosenthal SB, et al. Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a
strategy for treatment of cholestatic liver fibrosis. Proc Natl Acad Sci U S A 2021;118.
PMID: 34253615
|
|
|
|